Lilly Reports Results of Dual GIP and GIP-1 Receptor Agonist with Reduction in HbA1c and Body Weight
Shots:
- The P-II study involves assessing of four doses of GIP/GLP-1 RA- LY3298176 (1 mg- 5 mg- 10 mg- 15 mg) vs PBO and dulaglutide 1.5 mg in 200 patients with Type 2 Diabetes for 26 weeks
- P-II study results (GIP/GLP-1 RA (5/10/15 mg) vs dulaglutide and PBO): HbA1c reduction (-1.6% @5 mg- -2.0% @10 mg- and -2.4% @15 mg; vs -1.1% @1.5 mg vs 0.1%): HbA1c target (69.1% @5 mg- 90.0% @10 mg- and 77.4% @15 mg; vs 51.9% @1.5mg); Weight loss (-4.8 kg @5 mg- -8.7 kg@10 mg and -11.3 kg @15 mg vs -2.7 kg @1.5mg vs 0.4 kg)
- Lilly plans to initiate P-III SURPASS program trial for assessing safety and efficacy of GIP/GLP-1 RA for Type 2 Diabetes and is expected to begin in no later than early 2019 with its closure in 2021
Ref: Eli Lilly | Image: Pharmvestnik
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com